Worldwide revenue from the active pharmaceutical ingredients (API) market stood at US$192.3 billion in 2022, with the global market estimated to surge ahead at a Compound Annual Growth Rate (CAGR) of 4.2%, reaching a valuation of US$300.2 billion by the end of 2033.
The global market for active pharmaceutical ingredient market recorded a historic CAGR of 3.4% in the last six years from 2016 to 2022.
An active pharmaceutical ingredient (API) is a molecule or substance found in a finished product that exhibits pharmacological activity. APIs have a direct influence on the cure, diagnosis, mitigation, or prevention of target diseases and are responsible for restoring, changing, or correcting physiological functioning in humans.
The global prevalence of chronic diseases is steadily increasing, placing a significant health burden on national economies. Common chronic diseases include diabetes, cardiovascular disease, cancer, obesity, osteoporosis, and pulmonary illnesses, with cardiovascular diseases accounting for roughly half of all chronic disease-related deaths.
The pharmaceutical sector is expected to grow rapidly due to the increasing prevalence of diseases, greater use of medicines, and a growing geriatric population.
Key pharmaceutical companies are actively working to make Research and Development (R&D) more efficient and accelerate the process of bringing breakthrough pharmaceuticals to market. Efforts are being made to reduce the costs of drug development and manufacturing.
Key Market Growth Factors and Dynamics Active Pharmaceutical Ingredient Market:
Rising Global Prevalence of Chronic Diseases: The increasing incidence of chronic diseases, such as diabetes, cardiovascular diseases, cancer, obesity, osteoporosis, and pulmonary illnesses, is a significant driver for the API market. APIs play a crucial role in the development of drugs to treat and manage these chronic conditions.
Growing Geriatric Population: The global demographic shift toward an aging population is contributing to higher healthcare needs. The elderly population often requires medications for chronic conditions, leading to an increased demand for pharmaceuticals and, consequently, APIs.
Technological Advancements in Drug Development: Ongoing advancements in technology, including innovative manufacturing processes and analytical techniques, are improving the efficiency of drug development and production. Continuous Manufacturing (CM) technology, for example, is streamlining API production processes and reducing development timelines.
Increased Emphasis on Research and Development (R&D): Pharmaceutical companies are investing heavily in R&D to discover and develop new drugs. This emphasis on innovation is driving the demand for APIs as essential components in the formulation of novel pharmaceutical products.
Outsourcing of Manufacturing Activities: Pharmaceutical companies are increasingly outsourcing manufacturing activities to Contract Development and Manufacturing Organizations (CDMOs) to reduce costs and focus on core competencies. This trend is boosting the growth of the API market, as CDMOs specialize in the production of APIs.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2032 – By Product Type, Application, End-user, and Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa): https://www.persistencemarketresearch.com/market-research/active-pharmaceutical-ingredient-market.asp
Market Restraints and Challenges Active Pharmaceutical Ingredient Market:
Stringent Regulatory Compliance: Adhering to strict regulatory standards and compliance requirements poses a significant challenge for API manufacturers. Meeting these standards can be time-consuming and costly, impacting the overall development timeline and costs.
Complex Manufacturing Processes: The manufacturing of certain APIs involves complex processes, especially for biotechnological and high-potency drugs. Implementing and maintaining these intricate processes can be challenging, requiring specialized equipment and expertise.
Price Erosion in Generic Drugs: With the increasing demand for generic drugs, there is often intense competition, leading to price erosion. API manufacturers may face pressure to reduce prices, affecting profit margins and sustainability.
Intellectual Property Issues: The API market is influenced by intellectual property rights, and manufacturers may face challenges related to patent expiration and generic competition. Navigating intellectual property landscapes and legal issues can be complex and may impact market share.
Supply Chain Disruptions: Global events, such as pandemics, natural disasters, or geopolitical tensions, can disrupt the pharmaceutical supply chain. Dependencies on raw material suppliers and manufacturing facilities in different regions make the API market vulnerable to such disruptions.
Rising Manufacturing Costs: The cost of raw materials, energy, and compliance with environmental regulations can lead to increased manufacturing costs. Balancing the need for quality and compliance with cost-effectiveness is a continual challenge for API manufacturers.
Quality Control and Assurance: Maintaining high-quality standards is crucial in the pharmaceutical industry. API manufacturers must invest in robust quality control measures, and any lapses in quality assurance can lead to regulatory actions and reputational damage.
Market Mergers & Acquisitions:
Lonzas Acquisition of Capsugel (2017): Lonza, a Swiss multinational chemicals and biotechnology company, acquired Capsugel, a leading provider of dosage form solutions. This acquisition strengthened Lonzas position in the pharmaceutical and biotechnology market, offering integrated solutions from APIs to drug product manufacturing.
Pfizers Acquisition of Hospira (2015): Pfizer, a major pharmaceutical company, acquired Hospira, a global provider of injectable drugs and infusion technologies. This acquisition expanded Pfizers sterile injectables portfolio, including APIs used in the production of injectable drugs.
Mercks Acquisition of Sigma-Aldrich (2015): Merck KGaA, a German multinational pharmaceutical and chemical company, acquired Sigma-Aldrich, a leading life science and technology company. This acquisition enhanced Mercks position in the life science industry, providing a wide range of products, including APIs.
Dr. Reddys Laboratories Acquisition of OctoPlus (2013): Dr. Reddys Laboratories, an Indian multinational pharmaceutical company, acquired OctoPlus, a specialty pharmaceutical company. This acquisition aimed to strengthen Dr. Reddys capabilities in drug delivery technologies, including the development of complex APIs.
Cambrex Corporations Acquisition by Thermo Fisher Scientific (2019): Thermo Fisher Scientific acquired Cambrex Corporation, a leading provider of small-molecule APIs for drug development and manufacturing. This acquisition expanded Thermo Fishers capabilities in providing a comprehensive range of services to the pharmaceutical and biotechnology industry.
Albemarle Corporations Acquisition of API Business from W.R. Grace & Co. (2016): Albemarle Corporation, a global specialty chemicals company, acquired the Fine Chemistry Services (FCS) business from W.R. Grace & Co. This acquisition strengthened Albemarles position in the development and manufacturing of APIs and advanced intermediates.
Divis Laboratories Acquisition of Unit-II of PharmaZell (2021): Divis Laboratories, an Indian pharmaceutical company, acquired Unit-II of PharmaZell, a manufacturing facility in Germany. This acquisition aimed to enhance Divis manufacturing capabilities for APIs and intermediates.
Future outlook Development:
Advancements in Technology: Continued advancements in manufacturing technologies, including continuous manufacturing, process automation, and analytical techniques, will drive efficiency and reduce production costs. Adoption of innovative technologies will likely enhance the development and production of APIs.
Focus on Personalized Medicine: The growing trend toward personalized medicine, driven by advancements in genomics and targeted therapies, will influence the demand for specific and customized APIs. This shift may lead to increased R&D efforts and the development of APIs tailored to individual patient needs.
Increased Outsourcing to CDMOs: Contract Development and Manufacturing Organizations (CDMOs) are expected to play a crucial role in the API markets future. Pharmaceutical companies may increasingly rely on CDMOs to benefit from specialized expertise, cost savings, and flexibility in manufacturing.
Globalization of Supply Chains: The globalization of pharmaceutical supply chains will continue, with companies seeking to diversify and secure their supply sources. Collaborations and partnerships across borders will remain essential for ensuring a stable and resilient supply chain.
Sustainability and Environmental Responsibility: Environmental sustainability will be a key focus for the pharmaceutical industry, including API manufacturers. Companies are likely to invest in environmentally friendly processes, waste reduction, and energy-efficient manufacturing to align with global sustainability goals.
Increasing Demand for High-Potency APIs (HPAPIs): The rising prevalence of complex and targeted therapies, often requiring High-Potency APIs (HPAPIs), will drive demand for specialized manufacturing capabilities. Companies investing in HPAPI production are expected to be well-positioned in the market.
Key Players: Pfizer Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company
Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Hepalink Group, Lonza, Merck & Co. Inc.
Key Segments Covered in Active Pharmaceutical Ingredients:
By End User:
Middle East & Africa
FAQ’s Answered In our Report:
What is the current size and valuation of the global API market?
What factors are driving the growth of the API market?
Which therapeutic areas have the highest demand for APIs?
What are the key challenges and restraints faced by the API market?
How is the regulatory landscape impacting API manufacturing and distribution?
About Persistence Market Research:
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.
Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.
Persistence Market Research
Teerth Techno space, Unit B-704
Survey Number 103, Baner
Mumbai Bangalore Highway
Pune 411045 India
This press release first seen on Brilad